PURPOSE OF REVIEW: Schistosomiasis is one of the most prevalent parasitic diseases in the world, being present in more than 70 countries. Pulmonary hypertension is one of the several chronic complications of schistosomiasis; particularly in developing countries, schistosomiasis-associated pulmonary arterial hypertension might represent one of the most prevalent causes of pulmonary arterial hypertension. RECENT FINDINGS: New epidemiological data reinforce the importance of schistosomiasis in the context of pulmonary hypertension; furthermore, the inflammatory components of the pathophysiology of pulmonary hypertension associated with schistosomiasis have been recently explored, opening the perspective of new targets to be explored. Clinical and hemodynamic features of this particular complication of schistosomiasis, and the role of targeted therapies in this setting, have been better described in recent years. SUMMARY: The importance of schistosomiasis-associated pulmonary hypertension is now recognized with better knowledge about its pathophysiology and management. Nevertheless, there is a need for better understanding the predisposal factors (genetic, environmental and so on) for the development of pulmonary hypertension in schistosomiasis as a way to prevent it from occurring. Furthermore, better control programs to decrease disease transmission are still missing, ensuring that we will have to face this devastating complication of schistosomiasis for a long future.
PURPOSE OF REVIEW: Schistosomiasis is one of the most prevalent parasitic diseases in the world, being present in more than 70 countries. Pulmonary hypertension is one of the several chronic complications of schistosomiasis; particularly in developing countries, schistosomiasis-associated pulmonary arterial hypertension might represent one of the most prevalent causes of pulmonary arterial hypertension. RECENT FINDINGS: New epidemiological data reinforce the importance of schistosomiasis in the context of pulmonary hypertension; furthermore, the inflammatory components of the pathophysiology of pulmonary hypertension associated with schistosomiasis have been recently explored, opening the perspective of new targets to be explored. Clinical and hemodynamic features of this particular complication of schistosomiasis, and the role of targeted therapies in this setting, have been better described in recent years. SUMMARY: The importance of schistosomiasis-associated pulmonary hypertension is now recognized with better knowledge about its pathophysiology and management. Nevertheless, there is a need for better understanding the predisposal factors (genetic, environmental and so on) for the development of pulmonary hypertension in schistosomiasis as a way to prevent it from occurring. Furthermore, better control programs to decrease disease transmission are still missing, ensuring that we will have to face this devastating complication of schistosomiasis for a long future.
Authors: Jean Pierre Sibomana; Aloma Campeche; Roberto J Carvalho-Filho; Ricardo Amorim Correa; Helena Duani; Virginia Pacheco Guimaraes; Joan F Hilton; Biruk Kassa; Rahul Kumar; Michael H Lee; Camila M C Loureiro; Sula Mazimba; Claudia Mickael; Rudolf K F Oliveira; Jaquelina S Ota-Arakaki; Camila Farnese Rezende; Luciana C S Silva; Edford Sinkala; Hanan Yusuf Ahmed; Brian B Graham Journal: Front Immunol Date: 2020-12-10 Impact factor: 7.561
Authors: Edith Liliana Posada-Martínez; Luis Gerardo Gonzalez-Barrera; Kiera Liblik; Juan Esteban Gomez-Mesa; Clara Saldarriaga; Juan Maria Farina; Josefina Parodi; Zier Zhou; Manuel Martinez-Selles; Adrian Baranchuk Journal: Arq Bras Cardiol Date: 2022-05 Impact factor: 2.667
Authors: Rahul Kumar; Claudia Mickael; Biruk Kassa; Linda Sanders; Dan Koyanagi; Daniel Hernandez-Saavedra; Scott Freeman; Daniel Morales-Cano; Angel Cogolludo; Amy S McKee; Andrew P Fontenot; Ghazwan Butrous; Rubin M Tuder; Brian B Graham Journal: J Am Heart Assoc Date: 2019-07-24 Impact factor: 5.501